Bioatla Inc

NASDAQ BCAB

Data sourced from

and

Daily

Download Data

Bioatla Inc Price to Sales Ratio (P/S) on June 03, 2024: 44.84

Bioatla Inc Price to Sales Ratio (P/S) is 44.84 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Bioatla Inc 52-week high Price to Sales Ratio (P/S) is 87.43 on May 16, 2024, which is 94.97% above the current Price to Sales Ratio (P/S).
Bioatla Inc 52-week low Price to Sales Ratio (P/S) is 42.59 on May 31, 2024, which is -5.03% below the current Price to Sales Ratio (P/S).
Bioatla Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 62.69.

NASDAQ: BCAB

Bioatla Inc

CEO	Dr. Jay M. Short Ph.D.
IPO Date	Dec. 16, 2020
Location	United States
Headquarters	11085 Torreyana Road, San Diego, CA, United States, 92121
Employees	65
Sector	Healthcare
Industry	Biotechnology

Description

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Key trends